Spivak JL - Search Results

1

Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.

Spivak JL, Moliterno AR, Silver RT. Spivak JL, et al. N Engl J Med. 2006 Aug 17;355(7):737; author reply 738. doi: 10.1056/NEJMc061631. N Engl J Med. 2006. PMID: 16914715 No abstract available.

2

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.

Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Williams DM, et al. Among authors: spivak jl. Exp Hematol. 2007 Nov;35(11):1641-6. doi: 10.1016/j.exphem.2007.08.010. Epub 2007 Oct 17. Exp Hematol. 2007. PMID: 17920755 Free PMC article.

3

Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.

Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Moliterno AR, et al. Among authors: spivak jl. Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23. Exp Hematol. 2008. PMID: 18723264 Free PMC article.

4

Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.

Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR. Stein BL, et al. Among authors: spivak jl. Haematologica. 2010 Jul;95(7):1090-7. doi: 10.3324/haematol.2009.014407. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133898 Free PMC article.

5

Two clinical phenotypes in polycythemia vera.

Spivak JL, Considine M, Williams DM, Talbot CC Jr, Rogers O, Moliterno AR, Jie C, Ochs MF. Spivak JL, et al. N Engl J Med. 2014 Aug 28;371(9):808-17. doi: 10.1056/NEJMoa1403141. N Engl J Med. 2014. PMID: 25162887 Free PMC article.

6

Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era.

Kander EM, Moliterno AR, Rademaker A, Streiff MB, Spivak JL, Stein BL. Kander EM, et al. Among authors: spivak jl. J Natl Compr Canc Netw. 2016 Oct;14(10):1238-1245. doi: 10.6004/jnccn.2016.0133. J Natl Compr Canc Netw. 2016. PMID: 27697978

7

Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.

Moliterno AR, Hankins WD, Spivak JL. Moliterno AR, et al. Among authors: spivak jl. N Engl J Med. 1998 Feb 26;338(9):572-80. doi: 10.1056/NEJM199802263380903. N Engl J Med. 1998. PMID: 9475764 Free article.

8

Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Moliterno AR, Williams DM, Rogers O, Spivak JL. Moliterno AR, et al. Among authors: spivak jl. Blood. 2006 Dec 1;108(12):3913-5. doi: 10.1182/blood-2006-03-008805. Epub 2006 Aug 15. Blood. 2006. PMID: 16912229 Free PMC article. Clinical Trial.

9

Imatinib mesylate in polycythemia vera.

Spivak JL, Silver RT. Spivak JL, et al. Blood. 2004 Apr 15;103(8):3241; author reply 3241-2. doi: 10.1182/blood-2003-12-4248. Blood. 2004. PMID: 15070710 Free article. No abstract available.

10

The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis.

Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. Pemmaraju N, et al. Among authors: spivak jl. Leukemia. 2007 Oct;21(10):2210-2. doi: 10.1038/sj.leu.2404755. Epub 2007 May 17. Leukemia. 2007. PMID: 17507997 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

201 results

Search Page